Emcure Pharmaceuticals is locked in its upper circuit at RS. 1288.65, marking a sharp rise of 117.15 points or 10.00% from its previous close of RS. 1171.50 on the BSE.

The stock opened at RS. 1202.10 and touched a high of RS. 1288.65 and a low of RS. 1202.10 during the trading session. So far, 22,398 shares have changed hands.

Classified under the BSE group 'B', the stock with a face value of RS. 10 has seen a 52-week high of RS. 1577.50 on September 18, 2024, and a 52-week low of RS. 890.00 on April 7, 2025. Over the past week, the stock traded between RS. 1288.65 and RS. 1046.80. The company’s current market capitalization stands at RS. 24417.77 crore.

Promoter shareholding in Emcure stands strong at 77.92%, while institutional investors hold 6.51% and non-institutional investors own 15.57%.

In a key development, the company’s Board of Directors has approved the incorporation of a wholly-owned subsidiary named ‘Emcure Generics’ in Pune, Maharashtra. The subsidiary will focus on the manufacturing, promotion, sale, and distribution of pharmaceutical and related products. The decision was finalized during the board meeting held on May 22, 2025.

Emcure Pharmaceuticals is a prominent Indian pharmaceutical company known for developing, manufacturing, and globally marketing a wide range of products across multiple therapeutic areas.